Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey
Abstract Background Neurofibromatosis type 1 is an inherited condition with variable phenotypic expression and a high medical and social burden. The objectives of this patient survey were to better understand the real-world experiences of patients living with cutaneous neurofibromas (cNF), to percei...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-12-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-019-1265-4 |
| _version_ | 1831808862932434944 |
|---|---|
| author | Marlene Guiraud Athmane Bouroubi Roxane Beauchamp Arnaud Bocquet Jean-Marc Grégoire Isabelle Rauly-Lestienne Ignacio Blanco Pierre Wolkenstein Anne-Marie Schmitt |
| author_facet | Marlene Guiraud Athmane Bouroubi Roxane Beauchamp Arnaud Bocquet Jean-Marc Grégoire Isabelle Rauly-Lestienne Ignacio Blanco Pierre Wolkenstein Anne-Marie Schmitt |
| author_sort | Marlene Guiraud |
| collection | DOAJ |
| description | Abstract Background Neurofibromatosis type 1 is an inherited condition with variable phenotypic expression and a high medical and social burden. The objectives of this patient survey were to better understand the real-world experiences of patients living with cutaneous neurofibromas (cNF), to perceive their satisfaction and feelings about cNF current management (only laser and surgery are currently available), and to highlight their expectations of new therapeutic modalities. Results One hundred seventy patients from 4 European countries took part in the study, 65% (n = 110) were women and mean age was 39 years old. 96% (n = 164) of respondents have cNF on visible parts of the body and the survey confirmed that total number of cNF and visibility increase with age. Patients reported that cNF mainly impacts everyday mood, general daily life and social life. The visibility of cNF had a higher impact than their number. 92% (n = 156) of patients have a regular and multidisciplinary medical follow-up. The dermatologist is one of the most consulted healthcare professionals. 76% (n = 130) of respondents have treated their cNF: 65% (n = 111) had surgery and 38% (n = 64) had multiple laser sessions. Frequency of operations and regrowth of cNF were the two most unsatisfactory aspects with both treatments for patients. Indeed, after removal, new cNF appear in more than 75% (n = 128) of cases. As a future treatment, patients expected a topical (30%, n = 51) or oral medication (29%, n = 50). Around 2 out of 3 patients would agree to take it at least once a day or more for life but they would like a well-tolerated treatment. According to patients, the most important effectiveness criteria of a new treatment are to block cNF growth and reduce their number. 70% (n = 119) of patients would consider a future treatment moderately effective to very effective if it could clear 30% of cNF. Conclusions This first cNF European patient community survey confirmed that the visible stigma and unaesthetic aspect of cNF have an important impact on patients’ quality of life. The survey highlighted that patients were not entirely satisfied with the actual surgery and laser treatments and revealed their clear and realistic expectations for future treatment of cNF. |
| first_indexed | 2024-12-22T20:30:24Z |
| format | Article |
| id | doaj.art-d66d2cf1a4c74bed92a3ce2b1f743acb |
| institution | Directory Open Access Journal |
| issn | 1750-1172 |
| language | English |
| last_indexed | 2024-12-22T20:30:24Z |
| publishDate | 2019-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj.art-d66d2cf1a4c74bed92a3ce2b1f743acb2022-12-21T18:13:37ZengBMCOrphanet Journal of Rare Diseases1750-11722019-12-0114111110.1186/s13023-019-1265-4Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community surveyMarlene Guiraud0Athmane Bouroubi1Roxane Beauchamp2Arnaud Bocquet3Jean-Marc Grégoire4Isabelle Rauly-Lestienne5Ignacio Blanco6Pierre Wolkenstein7Anne-Marie Schmitt8Institut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation UnitInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation UnitInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation UnitInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation UnitInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation UnitInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation UnitGenetic Counseling and Clinical Genetics Program, Laboratori Clínic Metropolitana Nord, Hospital Germans TiasCHU Henri MondorInstitut de Recherche Pierre Fabre, Centre de Recherche et Développement, Dermatology Innovation UnitAbstract Background Neurofibromatosis type 1 is an inherited condition with variable phenotypic expression and a high medical and social burden. The objectives of this patient survey were to better understand the real-world experiences of patients living with cutaneous neurofibromas (cNF), to perceive their satisfaction and feelings about cNF current management (only laser and surgery are currently available), and to highlight their expectations of new therapeutic modalities. Results One hundred seventy patients from 4 European countries took part in the study, 65% (n = 110) were women and mean age was 39 years old. 96% (n = 164) of respondents have cNF on visible parts of the body and the survey confirmed that total number of cNF and visibility increase with age. Patients reported that cNF mainly impacts everyday mood, general daily life and social life. The visibility of cNF had a higher impact than their number. 92% (n = 156) of patients have a regular and multidisciplinary medical follow-up. The dermatologist is one of the most consulted healthcare professionals. 76% (n = 130) of respondents have treated their cNF: 65% (n = 111) had surgery and 38% (n = 64) had multiple laser sessions. Frequency of operations and regrowth of cNF were the two most unsatisfactory aspects with both treatments for patients. Indeed, after removal, new cNF appear in more than 75% (n = 128) of cases. As a future treatment, patients expected a topical (30%, n = 51) or oral medication (29%, n = 50). Around 2 out of 3 patients would agree to take it at least once a day or more for life but they would like a well-tolerated treatment. According to patients, the most important effectiveness criteria of a new treatment are to block cNF growth and reduce their number. 70% (n = 119) of patients would consider a future treatment moderately effective to very effective if it could clear 30% of cNF. Conclusions This first cNF European patient community survey confirmed that the visible stigma and unaesthetic aspect of cNF have an important impact on patients’ quality of life. The survey highlighted that patients were not entirely satisfied with the actual surgery and laser treatments and revealed their clear and realistic expectations for future treatment of cNF.https://doi.org/10.1186/s13023-019-1265-4Neurofibromatosis type 1Cutaneous neurofibromasPatient community surveyQuality of lifeFuture medicationReal-world experience |
| spellingShingle | Marlene Guiraud Athmane Bouroubi Roxane Beauchamp Arnaud Bocquet Jean-Marc Grégoire Isabelle Rauly-Lestienne Ignacio Blanco Pierre Wolkenstein Anne-Marie Schmitt Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey Orphanet Journal of Rare Diseases Neurofibromatosis type 1 Cutaneous neurofibromas Patient community survey Quality of life Future medication Real-world experience |
| title | Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey |
| title_full | Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey |
| title_fullStr | Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey |
| title_full_unstemmed | Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey |
| title_short | Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey |
| title_sort | cutaneous neurofibromas patients medical burden current management and therapeutic expectations results from an online european patient community survey |
| topic | Neurofibromatosis type 1 Cutaneous neurofibromas Patient community survey Quality of life Future medication Real-world experience |
| url | https://doi.org/10.1186/s13023-019-1265-4 |
| work_keys_str_mv | AT marleneguiraud cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey AT athmanebouroubi cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey AT roxanebeauchamp cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey AT arnaudbocquet cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey AT jeanmarcgregoire cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey AT isabelleraulylestienne cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey AT ignacioblanco cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey AT pierrewolkenstein cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey AT annemarieschmitt cutaneousneurofibromaspatientsmedicalburdencurrentmanagementandtherapeuticexpectationsresultsfromanonlineeuropeanpatientcommunitysurvey |